Innovative drugs accelerate internationalization, generic drugs need to break out of the era of meager profits, investment heat or fade...

The third pressure is rising prices for raw materials. In recent years, with the continuous introduction of innovative drugs to the market and the inclination of medical insurance to innovative drugs, the market share of innovative drugs has increased greatly, but generic drugs still occupy 68% of the domestic market share. After consistency evaluation, the cost of generic drugs increased. After the collection, the price of generic drugs has been sharply reduced, while the price of raw materials has been rising, such as vitamin E, captopril, cefixime and so on. The price increase of apis has brought great pressure to the entire industry, especially generic drug companies.

Lin Jianning also mentioned that the "Implementation Plan on Promoting high-quality development of API Industry" issued by the National Development and Reform Commission and the Ministry of Industry and Information Technology not long ago put forward higher requirements for environmental protection, and the future API competition will be the competition of standardization, raw materials, energy and environmental protection costs.

Wang Yiting: Digital marketing upgrade is imperative

At the meeting, Wang Yiting, head of Jingdong Health and Medicine Division, mentioned when analyzing the current development status of the Internet medicine industry that the epidemic has driven the rapid growth of the entire Internet medical industry. In 2020, the number of users of digital medical services has reached 620 million, and more than 60% of patients obtain medical information through the Internet. The fully released market demand in the 2020 epidemic, coupled with the complete diagnosis and treatment chain linked with the diagnosis and treatment link, has driven the transaction scale of the pharmaceutical e-commerce industry to break the 100 billion yuan mark and approach 200 billion yuan. It also predicts the new trend of pharmaceutical retail under the upgrade of digital marketing.

Talking about the key drivers of the "Internet + medicine" reform, Wang Yiting analyzed: first, the change of circulation channels, online circulation channels are favored by users, efficient distribution and complete categories, building the core advantages of online circulation; The second is the change of user demand, user demand from the purchase of drugs gradually extended to the direction of richer professional services, more diversified; Third, upstream demand changes, in the case of inefficient marketing means in the past, enterprises began to find new digital marketing channels, the core demands of digital marketing pharmaceutical companies.

So, how to build a new development model of medical e-commerce driven by user needs? Wang Yiting believes that "first of all, we should make full use of the drug supply." On the issue of "fast", the current online and offline operation model of medical e-commerce is enough to meet the needs of users' drug distribution, and the key issue is "full". Pharmaceutical e-commerce must be closer to the direction of full category coverage in order to fully cover the different drug purchase demands of different user groups. In the future, this new model of professional service pharmaceutical retail and marketing will become the 'standard' of the pharmaceutical e-commerce industry, always providing solutions around the needs of users, and providing users with a full range of medical health protection with a long-term sustainable service concept."

Geng Hongwu: Forecast of drug collection trend in 2022

So far, China has carried out six batches of drug procurement and two batches of high-value medical consumables procurement, centralized procurement system framework has been basically formed. During the "14th Five-Year Plan" period, under the guidance of the policy, what kind of development trend will China's centralized drug procurement show?

Geng Hongwu predicted that procurement with volume is the main feature of centralized procurement at this stage and will become a breakthrough in medical reform. In 2022, price reduction and cost control are still the main goals of centralized procurement at this stage, and drugs and consumables will enter a new stage of "cheap and high-quality". At the same time, the variety, region, and scope of medical insurance agreements will be further expanded, and the forms of volume procurement will be more diverse. Proprietary Chinese medicines, biological products and medical consumables will be included in the procurement scope.

In addition, the national, inter-provincial, regional alliance VBP, provincial direct network will become the main form. Alliance procurement becomes the direction required by the policy, and more types of alliance organizations will emerge. And classified procurement, different treatment, detailed rules are also the direction of centralized procurement. In the centralized procurement will be treated differently according to the characteristics of varieties and clinical requirements, and more detailed evaluation rules will be established. At the same time, the information system has been continuously improved, and the price and credit evaluation system has been widely used. The price and bidding credit evaluation system has become the requirements of centralized procurement, the standards followed by bidding enterprises and the reference for medical institutions to choose products.